Hematology
Conference Coverage
Biomarkers predict VTE risk with menopausal oral hormone therapy
CHICAGO – Pretreatment high D-dimer spells 500% increased VTE risk on oral hormone therapy.
FDA/CDC
Sickle cell infusion gains FDA breakthrough designation
The investigational therapy is aimed at preventing vasoocclusive crises.
News
Poor-prognosis cancers linked to highest suicide risk in first year
Pancreatic and lung cancer patients had high rates of suicide in comparison to the general population, while breast and prostate cancer patients...
Conference Coverage
Phase 3 data support apixaban for cancer-associated VTE
The rate of major bleeding was similar with apixaban and dalteparin.
Conference Coverage
NCI director: Data failures cost lives
SAN DIEGO – Too many patients die because numbers aren’t aggregated or shared, Dr. Ned Sharpless said at the ASH meeting.
Conference Coverage
2018: A banner year for hematology drug approvals
SAN DIEGO – There have been 32 new hematology drug approvals and the year isn’t over yet.
Video
Gut bacteria influence HCT outcomes
SAN DIEGO – Gut microbiome diversity predicts overall survival after hematopoietic cell transplant.
News
New data further support curability of myeloma
A study has found that a sizable share of transplant-eligible patients can expect to live as long as similar people in the general population.
News
ASH releases new VTE guidelines
A panel of the American Society of Hematology released more than 150 recommendations for dealing with venous thromboembolism.
Article
